TM-38837 is a cannabinoid receptor type 1 (CB1) antagonist potentially for the treatment of obesity and type 2 diabetes. CB1R occupancy increased in a dose/plasma concentration-dependent manner. [(11) C]MePPEP accumulation decreased in gall bladder and brown adipose tissue by TM38837 administration. TM38837 showed an estimated terminal half-life of 771 h. References: Takano A, Gulyás B, Varnas K, Little PB, Noerregaard PK, Jensen NO, Elling CE, Halldin C. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study. Synapse. 2014 Mar;68(3):89-97. doi: 10.1002/syn.21721. PubMed PMID: 24293119.

纯度：≥98%

CAS：1253641-65-4